In brief
- A study published in Translational Psychiatry directly compares, for the first time, the epigenetic marks left by ketamine and MDMA in individuals who received them during clinical trials.
- Ketamine altered DNA methylation at 1,210 points in the genome, while MDMA affected 2,074; both substances targeted genes linked to neuronal plasticity, often with opposing patterns.
- The authors present this as a first step toward potential biomarkers for treatment response, though they caution that the sample sizes are small (20 and 16 people) and the results are preliminary.
Ketamine and MDMA share a reputation as “psychoplastogens”—substances capable of opening windows of brain plasticity that facilitate therapeutic work in treatment-resistant depression, post-traumatic stress, and other conditions. A team of researchers has just published a study in Translational Psychiatry, a Nature Portfolio journal, that directly compares the epigenetic footprint each of these two molecules leaves in the bodies of those who receive them within a clinical trial.
What was measured and how
The work, designed as a brain-targeted epigenome-wide association study (BEWAS), analyzed blood samples from twenty people treated with ketamine and saliva samples from sixteen people who participated in MDMA trials, taken before and after treatment. The underlying logic is that, although it is impossible to biopsy the brain of a living person, certain chemical changes to DNA in peripheral tissues like blood or saliva may reflect biological processes occurring in the nervous system, acting as an indirect indicator of what happens following exposure to the substance.
Overlapping, yet distinct, footprints
Ketamine modified methylation at 1,210 genome positions, associated with 405 genes and 169 functional networks; MDMA affected 2,074 positions, 346 genes, and 183 networks. Both substances converged on pathways related to synaptic plasticity and the regulation of the brain’s immune system, sharing specific genes such as PTPRN2 and SHANK2, which are linked to the growth and reorganization of neuronal connections. However, at several of these common points, ketamine and MDMA shifted methylation in opposite directions. This suggests that, despite pursuing a similar goal—opening plasticity to allow therapy to “take hold”—each molecule does so through distinct molecular pathways.
What this implies
The authors themselves insist that this is a preliminary finding: twenty and sixteen people are small samples for an analysis examining hundreds of thousands of points in the genome, and a statistical association does not prove that these epigenetic changes are the cause of clinical improvement, nor that they persist over time. It is also not yet clear whether these marks in blood or saliva faithfully reflect what happens in the brain. Even with these caveats, the study provides another piece of the puzzle to understand why two substances so different in their pharmacology—one a dissociative, the other an entheogen—can share therapeutic utility: not because they act the same way, but because they converge on the brain’s capacity to reorganize itself. This type of evidence, read without drama or premature promises, is what could eventually help refine which substance is best suited for each person and each diagnosis, beyond the legal or commercial availability of each.
Source
- Translational Psychiatry (Nature Portfolio). Brain-targeted epigenetic effects of two emerging psychoplastogens: ketamine & MDMA. Translational Psychiatry, July 11, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
